Senseonics reported third quarter 2026 net revenue of $19.6 million , up roughly 140% year over year and well above consensus estimates near $16.2 million. U.S. revenue climbed about 160% to $16.8 million, while revenue outside the U.S. rose roughly 65% to $2.8 million.
Total revenue reached $35.1 million in the third quarter of 2026, up about 71% year over year and well above the roughly $25.6 million consensus estimate. Diluted earnings came in at $0.17 per share, a sharp reversal from the $0.10-per-share loss analysts had expected, with net income of $7.0 million.
The central target of $26 is the arithmetic mean of five verified analyst price targets reviewed for Delcath Systems, Inc. (DCTH) , rounded from roughly $25.8. At the latest verified close of $20.27, reaching $26 implies a substantial move of roughly 28% .
SENS jumped from its prior close of $8.59 to roughly $9.81, a gain of about +14.1%, during regular market hours on Monday. The advance reflects pre-earnings positioning ahead of Senseonics' Q3 2026 report scheduled for after the close, following Q2's ~120% year-over-year revenue growth and raised full-year guidance.
The central target of $13 is the arithmetic mean of six verified analyst price targets reviewed for Senseonics Holdings, Inc. (SENS) , a commercial-stage maker of implantable continuous glucose monitoring (CGM) systems. With the stock recently trading near $9.51, reaching $13 would require roughly a 37% rise — a substantial, though not extreme, move.
TMCI surged +19.11% to $4.80 from Friday's $4.03 close, with the move occurring during Monday's regular session. The rally followed analyst upgrades: Stifel lifted the stock to Buy with a $6.50 price target (up from $4.50) and UBS moved to Buy from Neutral, after Q3 results beat estimates and adjusted EBITDA turned positive for the first non-seasonal quarter since its 2021 IPO.
TMCI shares advanced roughly 22% over the trailing 30 days, climbing from about $3.95 to $4.83. The move was fueled by a third-quarter earnings beat, a swing to positive adjusted EBITDA, and two analyst upgrades to Buy.
The central $26 stock price target is the arithmetic mean of five recently updated analyst targets, which range from $21 to $32. With shares recently near $14.93, reaching $26 would require a gain of roughly 74%, a very large move.
The central target of $7.50 is drawn from public discussion and AI-model-driven estimates, not a traditional analyst consensus, because TRIB has no credible, current analyst price targets. With the stock recently trading near $5.70 , reaching $7.50 would require an upside of roughly 32% .
Trinity Biotech (TRIB) slipped from a previous close of $5.70 to $5.54, down -2.81%, during regular market hours. No verified news or fundamental catalyst found. The decline is consistent with the stock's ongoing multi-month downtrend and routine volatility—it typically swings several percent each session, and this -2.81% move is actually below its roughly 5-6% average daily range.
AIDX (20/20 BioLabs) ticked up +1.38% during the regular session, rising from a $0.1963 prior close to about $0.199 in midday trading. No verified news or fundamental catalyst found. The modest gain is likely a quiet drift in a low-priced micro-cap that routinely moves several percent per session.
NNOX fell from $0.24 to $0.23, a -4.17% decline, during regular trading hours. No verified news or fundamental catalyst found. The drop is consistent with the stock's ongoing downtrend, down roughly -84% year-to-date on going-concern doubts and heavy cash burn, and this move sits well within its typical daily range.
The central $220 target is the average of verified analyst price targets that sit above the latest price, rounded to a clean level. Shares last closed near $197.88 , so reaching $220 would require a gain of roughly 11% .
PMI dropped -6.44% during regular market hours, sliding from Friday's $9.00 close to $8.42 as of mid-morning trading. No verified news or fundamental catalyst found. The decline is consistent with this micro-cap's speculative trading pattern — shares routinely swing by double digits, with a typical daily move of roughly 12.8% and 32 of the last 60 sessions moving at least as much as today.
The $5.50 objective is a fallback recovery target, not an analyst consensus: it reflects a potential reclaim of the roughly $5.73 level where the stock closed on Nov. 4, 2026, before a sharp single-day decline. SANUWAVE Health, Inc. ( SNWV ) is a micro-cap medical-device company focused on wound care; it is a common stock, not an exchange-traded fund (ETF).
The central target of $2.25 is the arithmetic mean of five recent analyst price targets reviewed, ranging from $1.25 to $5.00 — not a single firm's forecast or an official published consensus. The stock trades near $0.87 after a sharp single-session decline following a third-quarter revenue miss and a cut to full-year guidance.
CVRx shares fell -10.34% to about $0.78 from Friday's $0.87 close, with the decline unfolding during regular trading hours. The move extends Friday's post-earnings rout: Q3 results reported Nov. 5 missed revenue estimates, management cut FY26 guidance, and flagged worsening Medicare Advantage reimbursement headwinds, followed by several analyst downgrades.
SNWV fell from a $2.19 prior close to $1.93 during regular market hours, a decline of -11.87%. The drop extends the selloff triggered by CMS's final 2027 Medicare Physician Fee Schedule, announced Nov 5, which cut reimbursement for the company's core UltraMIST wound-care code by roughly -21% and sent shares down about -60% that session.
The central target used here is $25, the arithmetic mean of seven verified analyst price targets ranging from roughly $15 to $52. At a recent price near $13.28, reaching $25 would require a gain of about 88% — a very large move by any standard.
NovoCure (NVCR) fell from Friday's close of $13.28 to $12.86, a -3.16% decline, with the slide beginning in premarket trading and extending into the regular session. The FDA issued a "Not Approvable" letter for NovoCure's Premarket Approval application for Optune Mya (brain metastases from non-small cell lung cancer), citing uncertainty over the therapy's degree of clinical benefit.